<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01558752</url>
  </required_header>
  <id_info>
    <org_study_id>2010913-01H</org_study_id>
    <nct_id>NCT01558752</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of a Metal on Poly Component Versus CORAIL Stem: A Bone Mineral Density Study</brief_title>
  <official_title>A Randomized Clinical Trial of a Modular Cementless Acetabular Metal on Poly Component Versus a Monoblock Cementless Titanium Shell With Ceramic on Ceramic Bearing and CORAIL Stem: A Bone Mineral Density Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal is to prospectively evaluate bone mineral density adjacent to the femoral&#xD;
      component and femoral bone remodeling of two different designs: CORAIL impaction broach&#xD;
      titanium stem compared to a modular titanium femoral stem (Tri-lock). Patients will be&#xD;
      randomized to one of the two treatment groups prior to surgery. Each patient will be&#xD;
      evaluated at their regularly scheduled 10-14 days, 3, 6, 12 and 24 month visits following&#xD;
      surgery. Patients will be asked to have bilateral DEXA bone mineral density tests (10-14 days&#xD;
      post-surgery, and 6, 12 and 24 months post-operatively). Urine and serum samples (measures of&#xD;
      bone turnover) will be collected at 3, 6 and 12 months post-operatively after an overnight&#xD;
      fast. Patient reported questionnaires will be completed preoperatively and at the 3, 6, 12,&#xD;
      and 24 month visits.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main goal is to prospectively evaluate bone mineral density adjacent to the femoral&#xD;
      component and femoral bone remodeling of two different designs: CORAIL impaction broach&#xD;
      titanium stem compared to a modular titanium femoral stem (Tri-lock). The investigators&#xD;
      expect the CORAIL femoral stem group to show significantly less bone loss on the femoral side&#xD;
      as compared to the Tri-lock group. The primary outcome is percent change in bone mineral&#xD;
      density (BMD) (g/cm2) from baseline (10-14 days post-op) to the two year post-operative&#xD;
      interval, as measured radiographically in zones 1 and 7.&#xD;
&#xD;
      Patients will be randomized to one of the two treatment groups prior to surgery. Each patient&#xD;
      will be evaluated at their regularly scheduled 10-14 days, 3, 6, 12 and 24 month visits&#xD;
      following surgery.&#xD;
&#xD;
      Bilateral DXA bone mineral density tests will be performed at 10-14 days following surgery&#xD;
      (baseline assessment) and at 6, 12, and 24 months post-operatively.&#xD;
&#xD;
      Urine and serum samples (measures of bone turnover) will be collected at 3, 6 and 12 months&#xD;
      post-operatively after an overnight fast.&#xD;
&#xD;
      The Harris Hip Score will be completed at each post-operative visit except the immediate&#xD;
      (10-14 days), when risk of dislocation precludes a determination of range of motion. At the&#xD;
      3, 6, 12 and 24 month post-operative visits, the patient will complete the SF-36 Item Health&#xD;
      Survey, WOMAC and UCLA activity scale.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2010</start_date>
  <completion_date type="Actual">November 20, 2020</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Bone Mineral Density</measure>
    <time_frame>2 Years Post-operative</time_frame>
    <description>To prospectively evaluate bone mineral density adjacent to the femoral component and femoral bone remodeling for the 2 groups. Bone mineral density was assessed using high-sensitivity dual x-ray absorptiometry region-free analysis (DXA-RFA). Mean number of pixels with change with significant BMD decrease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Bone Turnover Markers Between Groups</measure>
    <time_frame>2 Years post-operative</time_frame>
    <description>Biochemical markers of bone turnover will be assessed from morning-fasting serum samples and compared from baseline to 2-years post-operative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant Migration</measure>
    <time_frame>2 years post-operative</time_frame>
    <description>Stem and cup migration will be assessed using radiographic images at baseline and 2-years post-operative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Modified Harris Hip Score</measure>
    <time_frame>2 Years post-operative</time_frame>
    <description>The change from baseline to 2-years post-operative on the Modified Harris Hip Score (mHHS). The mHHS assesses a patient's functional outcome and pain. The maximum score is 100 and the lowest is 0. A higher score is indicative of better outcomes and lower pain levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36 Score</measure>
    <time_frame>2 Years post-operative</time_frame>
    <description>The change from baseline to 2-years post-operative on the SF-36 score: a quality of-life measure. The score consists of 36 questions separated into 8 concepts. These outcomes will be grouped as physical component summary and mental component summary. The norm data is 0-100. The health related quality of life is increases as the scores are increased. The average score is 50.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WOMAC Questionnaire</measure>
    <time_frame>2 Years post-operative</time_frame>
    <description>The change from baseline to 2-years post-operative on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). The WOMAC score consists of 24 items, separated into 3 subscales. Each question is scored on a scale of 0 to 4, with a possible score range of 0-20 for pain, 0-8 for stiffness, and 0-68 for physical function. The scores of each subscale are summed to give a total score. Higher scores are indicative of worse pain, stiffness and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in UCLA Activity Scale</measure>
    <time_frame>2 Years post-operatively</time_frame>
    <description>The change from baseline to 2-years post-operative on the UCLA Activity score. The UCLA activity scale is a 10 point scale evaluating a patients activity level. The possible score range is from 0-10. A low value is indicative of sedentary or inactivity, whereas a high score is indicative of high levels of activity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Total Hip Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Titanium Shell with CORAIL stem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in Group 1 will receive a total hip replacement with titanium shell and CORAIL stem.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modular Titanium Femoral Stem (Tri-Lock)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in Group 2 will receive a total hip replacement with Modular Titanium Femoral Stem (Tri-lock).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Total hip replacement with titanium shell and CORAIL stem</intervention_name>
    <description>Patients that are randomized into Group 1 will receive a total hip replacement with the following components: CORAIL (impaction broach) titanium stem and a monoblock cup with ceramic on ceramic bearing (DELTA motion).</description>
    <arm_group_label>Titanium Shell with CORAIL stem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Total hip replacement with Modular Titanium Femoral Stem</intervention_name>
    <description>Patients that are randomized into Group 2 will receive a total hip replacement with the following components: the Trilock-Pinnacle system (titanium stem and titanium cup with polyethylene insert).</description>
    <arm_group_label>Modular Titanium Femoral Stem (Tri-Lock)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are undergoing primary hip surgery for osteo/degenerative arthritis (does&#xD;
             not include traumatic arthritis, congenital hip dysplasia, or avascular necrosis).&#xD;
&#xD;
          -  Patients who are skeletally mature, as determined by Risser sign or at least 18 years&#xD;
             of age&#xD;
&#xD;
          -  Patients under 75 years of age&#xD;
&#xD;
          -  Patients for whom there is a reasonable expectation that they will be available for&#xD;
             each examination scheduled over a two year post-operative follow-up period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with previous fusions, acute femoral neck fractures and above knee&#xD;
             amputations.&#xD;
&#xD;
          -  Patients with evidence of active local infection&#xD;
&#xD;
          -  Patients with neurologic or musculoskeletal disease that may adversely affect gait or&#xD;
             weight-bearing.&#xD;
&#xD;
          -  Patients who have previously undergone an ipsilateral hemi resurfacing, total&#xD;
             resurfacing, total bipolar, unipolar or total hip replacement device, or any prior hip&#xD;
             surgery or retained internal fixation.&#xD;
&#xD;
          -  Patients who are anticipated to require contralateral hip surgery in the next year&#xD;
&#xD;
          -  Patients with known disorders of bone metabolism, systemic inflammatory disorders, and&#xD;
             use of drug medications, including oral steroids, HRT, Tamoxifen, calcium, or vitamin&#xD;
             D in the past year, and any past bisphosphonate therapy.&#xD;
&#xD;
          -  Patients with a Body Mass Index (BMI) &gt; 35&#xD;
&#xD;
          -  Patients with neuropathic joints&#xD;
&#xD;
          -  Patients with severe documented psychiatric disease&#xD;
&#xD;
          -  Patients requiring structural bone grafts&#xD;
&#xD;
          -  Patients with an ipsilateral girdlestone&#xD;
&#xD;
          -  Patients with sickle cell disease&#xD;
&#xD;
          -  Patients with major acetabular bone stock deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul E Beaulé, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ottawa Hospital - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Slullitel PA, Mahatma MM, Farzi M, Grammatopoulos G, Wilkinson JM, Beaulé PE. Influence of Femoral Component Design on Proximal Femoral Bone Mass After Total Hip Replacement: A Randomized Controlled Trial. J Bone Joint Surg Am. 2021 Jan 6;103(1):74-83. doi: 10.2106/JBJS.20.00351.</citation>
    <PMID>33079901</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 16, 2012</study_first_submitted>
  <study_first_submitted_qc>March 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2012</study_first_posted>
  <results_first_submitted>November 23, 2020</results_first_submitted>
  <results_first_submitted_qc>November 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 19, 2020</results_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Total Hip Replacement</keyword>
  <keyword>Bone Mineral Density</keyword>
  <keyword>Stem</keyword>
  <keyword>Dual-energy x-ray absorptiometry</keyword>
  <keyword>DXA-RFA</keyword>
  <keyword>Corail</keyword>
  <keyword>Tri-Lock</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 7, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT01558752/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Corail</title>
          <description>Patients in Group 1 will receive a total hip replacement with titanium shell and CORAIL stem.&#xD;
Total hip replacement with titanium shell and CORAIL stem: Patients that are randomized into Group 1 will receive a total hip replacement with the following components: CORAIL (impaction broach) titanium stem and a monoblock cup with ceramic on ceramic bearing (DELTA motion).</description>
        </group>
        <group group_id="P2">
          <title>Tri-Lock</title>
          <description>Patients in Group 2 will receive a total hip replacement with Modular Titanium Femoral Stem (Tri-lock).&#xD;
Total hip replacement with Modular Titanium Femoral Stem: Patients that are randomized into Group 2 will receive a total hip replacement with the following components: the Trilock-Pinnacle system (titanium stem and titanium cup with polyethylene insert).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Corail</title>
          <description>Patients in Group 1 will receive a total hip replacement with titanium shell and CORAIL stem.&#xD;
Total hip replacement with titanium shell and CORAIL stem: Patients that are randomized into Group 1 will receive a total hip replacement with the following components: CORAIL (impaction broach) titanium stem and a monoblock cup with ceramic on ceramic bearing (DELTA motion).</description>
        </group>
        <group group_id="B2">
          <title>Tri-Lock</title>
          <description>Patients in Group 2 will receive a total hip replacement with Modular Titanium Femoral Stem (Tri-lock).&#xD;
Total hip replacement with Modular Titanium Femoral Stem: Patients that are randomized into Group 2 will receive a total hip replacement with the following components: the Trilock-Pinnacle system (titanium stem and titanium cup with polyethylene insert).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="10.2"/>
                    <measurement group_id="B2" value="60.4" spread="10.1"/>
                    <measurement group_id="B3" value="59.4" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>American Society of Anesthesiologists (ASA) Grade</title>
          <description>The ASA grade is a physical status classification system that is used for assessing the fitness and co-morbidities of patients before surgery. Patients are categorized between grades 1-6, with a lower grade indicative of better health and less co-morbidities.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Grade 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Bone Mineral Density</title>
        <description>To prospectively evaluate bone mineral density adjacent to the femoral component and femoral bone remodeling for the 2 groups. Bone mineral density was assessed using high-sensitivity dual x-ray absorptiometry region-free analysis (DXA-RFA). Mean number of pixels with change with significant BMD decrease.</description>
        <time_frame>2 Years Post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Corail</title>
            <description>Patients in Group 1 will receive a total hip replacement with titanium shell and CORAIL stem.&#xD;
Total hip replacement with titanium shell and CORAIL stem: Patients that are randomized into Group 1 will receive a total hip replacement with the following components: CORAIL (impaction broach) titanium stem and a monoblock cup with ceramic on ceramic bearing (DELTA motion).</description>
          </group>
          <group group_id="O2">
            <title>Tri-Lock</title>
            <description>Patients in Group 2 will receive a total hip replacement with Modular Titanium Femoral Stem (Tri-lock).&#xD;
Total hip replacement with Modular Titanium Femoral Stem: Patients that are randomized into Group 2 will receive a total hip replacement with the following components: the Trilock-Pinnacle system (titanium stem and titanium cup with polyethylene insert).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bone Mineral Density</title>
          <description>To prospectively evaluate bone mineral density adjacent to the femoral component and femoral bone remodeling for the 2 groups. Bone mineral density was assessed using high-sensitivity dual x-ray absorptiometry region-free analysis (DXA-RFA). Mean number of pixels with change with significant BMD decrease.</description>
          <units>number of pixels with change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1072" spread="50"/>
                    <measurement group_id="O2" value="1295" spread="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Bone Turnover Markers Between Groups</title>
        <description>Biochemical markers of bone turnover will be assessed from morning-fasting serum samples and compared from baseline to 2-years post-operative.</description>
        <time_frame>2 Years post-operative</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Implant Migration</title>
        <description>Stem and cup migration will be assessed using radiographic images at baseline and 2-years post-operative.</description>
        <time_frame>2 years post-operative</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Modified Harris Hip Score</title>
        <description>The change from baseline to 2-years post-operative on the Modified Harris Hip Score (mHHS). The mHHS assesses a patient's functional outcome and pain. The maximum score is 100 and the lowest is 0. A higher score is indicative of better outcomes and lower pain levels.</description>
        <time_frame>2 Years post-operative</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SF-36 Score</title>
        <description>The change from baseline to 2-years post-operative on the SF-36 score: a quality of-life measure. The score consists of 36 questions separated into 8 concepts. These outcomes will be grouped as physical component summary and mental component summary. The norm data is 0-100. The health related quality of life is increases as the scores are increased. The average score is 50.</description>
        <time_frame>2 Years post-operative</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in WOMAC Questionnaire</title>
        <description>The change from baseline to 2-years post-operative on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). The WOMAC score consists of 24 items, separated into 3 subscales. Each question is scored on a scale of 0 to 4, with a possible score range of 0-20 for pain, 0-8 for stiffness, and 0-68 for physical function. The scores of each subscale are summed to give a total score. Higher scores are indicative of worse pain, stiffness and functional limitations.</description>
        <time_frame>2 Years post-operative</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in UCLA Activity Scale</title>
        <description>The change from baseline to 2-years post-operative on the UCLA Activity score. The UCLA activity scale is a 10 point scale evaluating a patients activity level. The possible score range is from 0-10. A low value is indicative of sedentary or inactivity, whereas a high score is indicative of high levels of activity.</description>
        <time_frame>2 Years post-operatively</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected at each standard of care clinical visit (10-14 days post-op, 3-, 6-, 12- and 24-months post-operative).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Corail</title>
          <description>Patients in Group 1 will receive a total hip replacement with titanium shell and CORAIL stem.&#xD;
Total hip replacement with titanium shell and CORAIL stem: Patients that are randomized into Group 1 will receive a total hip replacement with the following components: CORAIL (impaction broach) titanium stem and a monoblock cup with ceramic on ceramic bearing (DELTA motion).</description>
        </group>
        <group group_id="E2">
          <title>Tri-Lock</title>
          <description>Patients in Group 2 will receive a total hip replacement with Modular Titanium Femoral Stem (Tri-lock).&#xD;
Total hip replacement with Modular Titanium Femoral Stem: Patients that are randomized into Group 2 will receive a total hip replacement with the following components: the Trilock-Pinnacle system (titanium stem and titanium cup with polyethylene insert).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Superficial wound infection</sub_title>
                <description>Superficial wound infection 1 month post-op requiring irrigation and debridement (I&amp;D) surgery.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Aseptic Loosening</sub_title>
                <description>Aseptic loosening is considered a relatively common complication of hip joint replacements. The patient generally experiences a great deal of pain and requires revision surgery.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Intra-operative Calcar Fracture</sub_title>
                <description>The incidence of intraoperative calcar fractures, a known complication of total hip arthroplasty (THA).</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Thigh pain</sub_title>
                <description>Participants that reported greater than normal pain levels in the thigh area.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Femoral nerve palsy</sub_title>
                <description>Femoral nerve dysfunction is a loss of movement or sensation in parts of the legs due to damage to the femoral nerve and is a complication that occurs during surgery.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Paul Beaule</name_or_title>
      <organization>The Ottawa Hospital Research Institute</organization>
      <phone>613-737-8899 ext 73265</phone>
      <email>pbeaule@toh.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

